Abstract. The present study aimed to investigate the association between the methylation status of the reversion-inducing cysteine-rich protein with kazal motifs (RECK) gene and its mRNA expression levels in patients with esophageal squamous cell carcinoma (ESCC). The methylation status of RECK was analyzed by methylation-specific polymerase chain reaction (PCR), and RECK mRNA expression levels were analyzed by quantitative PCR, in 310 paired ESCC tissues. The mean RECK methylation index (MI) was 0.65 in ESCCs and 0.49 in non-tumor samples. There was a significant association between RECK methylation and the American Joint Committee on Cancer stage and lymph node metastasis in ESCC (P<0.0001; P=0.001). The mRNA expression level of RECK was lower in ESCC tissues (mean -∆Cq =-4.66) compared with non-tumor tissues (mean -∆Cq =-2.79), and decreased RECK mRNA expression levels were associated with lymph node metastasis in ESCC. In addition, RECK mRNA levels were decreased in ESCC patients with hypermethylation of the RECK gene (∆MI >0.16; mean -∆∆Cq =-2.85) compared with those with hypomethylation of the RECK gene (∆MI ≤0.16; mean -∆∆Ct =-0.83), and there was a significant difference in the mRNA expression levels of RECK between those with N 0-1 and N 2-3 lymph node metastasis (P<0.0001). A significant correlation was observed between RECK mRNA expression levels, the MI of RECK and poor postoperative survival (P=0.0003; P<0.0001). The results of the present study suggested that promoter hypermethylation may be an important factor for loss of RECK mRNA expression and may be an indicator of poor survival in ESCC.
Introduction
The incidence of esophageal squamous cell carcinoma (ESCC) shows geographical variation and the highest rates have been reported in China (1) . A number of risk factors have been reported for ESCC, including dietary factors, bad behavioral habits, socioeconomic status and genetics (1, 2) . Research has identified numerous molecular markers, particularly for the early stage of ESCC (1, 2) . Therefore, it is important to investigate molecular alterations in tumors and precancerous lesions for the early detection or classification of ESCC (1) .
The vascular endothelial growth factor (VEGF)-A gene may be an important marker in the development and progression of ESCC in Chinese populations (3) . The aberrant methylation of tumor related-genes, such as fragile histidine triad, E-cadherin and integrin-α4, has been reported to be an independent adverse prognostic factor in ESCC (4, 5) . Clinicopathological and molecular investigations of early squamous cell carcinoma in precancerous lesions and early-stage ESCCs have identified effective biomarkers to predict the risk of patients with dysplasia, the infiltration depth of tumors, and lymph node metastasis and vascular invasion (4) (5) (6) .
Reversion-inducing cysteine-rich protein with kazal motifs (RECK) is a novel tumor suppressor gene that negatively regulates matrix metalloproteinases (MMPs). RECK is expressed in various normal human tissues, but is downregulated in several types of human tumors and has been positively correlated with the survival of patients with cancer (7) (8) (9) (10) . Furthermore, RECK is hypothesized to be involved in the maturation of blood vessels, and RECK and cluster of differentiation (CD) 34 (a known vessel marker) exhibited a strong positive correlation in glioma (11) . In addition, there is a significant correlation between RECK gene expression and the formation of new blood vessels by VEGF (12) , and the expression of RECK was associated with VEGF and CD105, which have an important role in esophageal carcinoma (13) .
A previous study reported that hypoxia was able to induce RECK silenced by histone deacetylase (HDAC) 1 and the interaction of hypoxia-inducible factor (HIF)-1α with the reverse HRE2 site in the promoter, and that downregulation of RECK may be a therapeutic and preventive target for tumorigenesis (14) . The inhibition of HDAC by small interfering (15) . It has been suggested that the binding activity of HIF-1α is important for the activation of the RECK promoter under hypoxic conditions (16) . Furthermore, the results of a previous study supported the notion that RECK dsRNA formation in the promoter region has the potential to upregulate RECK gene expression (17) . Gene promoter hypermethyla tion has been associated with the silencing of tumor-related genes, which is considered the most important epigenetic dis ruption in numerous tumors (18, 19) . In a previous study, hypermethylation of the RECK gene was partially reversed by epigallocatechin gallate treatment, and the mRNA expression level of RECK was significantly enhanced in oral squamous cell carcinoma cell lines (20) . RAS was able to increase the binding of DNA methyltransferase (DNMT) 3B to the RECK promoter and induce promoter methylation, while treatment with 5'-azacytidine and DNMT3B-targeting siRNA restored RECK expression and potently suppressed cell invasion (21) . These results suggested that RECK methylation may be an important regulatory mechanism of RECK expression in ESCC. However, the molecular mechanism underlying this downregulation and its biological significance in ESCC remain unclear. Furthermore, no studies have investigated RECK methylation and RECK mRNA expression in ESCC. The present study aimed to investigate the relationship between RECK mRNA expression and promoter methylation in ESCC.
Materials and methods
Patients and tissue samples. Tumor and non-tumor samples were obtained by surgical resection from 310 ESCC patients between May 2001 and June 2014. These specimens were collected from Changzhou Cancer Hospital and Nanyang Center Hospital in China. The matched non-tumor tissues were obtained from >3 cm away from the tumors and were confirmed to be tumor-free by microscopic examination. The tissues were maintained at -196˚C until processing for RNA/DNA extraction. The patients included 180 men and 130 women, and ranged in age from 36-82 years (mean age, 52.47±12.43 years). In total, 88 cases were well-differentiated, 142 were moderately-differentiated and 80 were poorly-differentiated. The present study was approved by the committee on Human Experimentation of Soochow University (Changzhou, China). Written informed consent was obtained from all patients.
RECK promoter methylation analysis. Tissue DNA was isolated using the Commercial QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany). Bisulfite modification of the DNA was performed using the EpiSeeker DNA Purification and Modification kit (Abcam, Cambridge, MA, USA) as described previously (22), and RECK methylation was measured by methylation-specific polymerase chain reaction (PCR) (19) . Unmethylated RECK primers were as follows: Forward, 5'-TAA AGA GTT TTG GTA TGG GGT ATG T-3' and reverse, 5'-CTC CAA ACC ACA AAA TAC TCA AA-3'. Methylated RECK primers were: Forward, 5'-AAT AAA GAG TTT TGG TAC GGG GTA C-3' and reverse, 5'-AAA ACC GCG AAA TAC TCG AA-3'. Modified DNA samples (2 µl) were used for PCR amplification. PCR was performed in a thermal cycler for 40 cycles. The conditions for PCR were denaturation at 95˚C for 30 sec, annealing at 58˚C for 30 sec and extension at 72˚C for 30 sec. The PCR products were separated on 2% agarose gels and visualized by ethidium bromide staining. The methylation index (MI) of RECK was calculated using the following formula: MI = 100 x methylated reaction / (unmethylated reaction + methylated reaction) (23) . ΔMI was defined as MI ESCC -MI Non-tumor .
RECK mRNA quantitative analysis. Total RNA was isolated from 310 ESCC and adjacent normal tissues using TRIzol reagent (Takara Biotechnology Co., Ltd., Dalian, China). First-strand cDNA was synthesized from 2 µg total RNA using PrimeScript™ RT Reagent kit (Takara Biotechnology Co., Ltd.). RECK mRNA primers were as follows: Forward, 5'-CCT CAG TGA GCA CAG TTC AGA-3' and reverse, 5'-GCA GCA CAC ACA CTG CTG TA-3' (19) . Quantitative PCR (qPCR) was performed using 20 µl SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) on the Mx3000P QPCR System (Agilent Technologies, Inc., Santa Clara, CA, USA). qPCR was performed for 40 cycles of 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min. β-actin mRNA was amplified from the same cDNA samples as an internal control. All results were normalized to β-actin. The relative RECK expression level was determined using the comparative Cq method (24), using average Cq values for RECK and β-actin.
Statistical analysis. The clinical data, MI and mRNA expression levels were analyzed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Comparisons were performed using Pearson's χ 2 test, or unpaired or paired t-tests. All P-values are two-sided, and a P-value of <0.05 was considered statistically significant. Survival curves were based on Kaplan-Meier estimates.
Results

MI of the RECK gene in tissues.
The methylation status of the RECK gene was analyzed in 310 ESCC and non-tumor tissues. The methylated PCR product contains methylated and/or unmethylated PCR products (25) . It was observed that the mean MI of the RECK gene was 0.65 [95% confidence interval (CI)= 0.62 to 0.68] in ESCC and 0.49 (95% CI= 0.47 to 0.51) in non-tumor samples, which was significantly different (P<0.0001; Fig. 1 ). These results suggest that the RECK promoter is hypermethylated in ESCC compared with non-tumor samples.
RECK methylation and clinicopathological features of ESCC.
Associations between the RECK methylation level and the clinical characteristics of ESCC patients, including age, gender, American Joint Committee on Cancer (AJCC) stage, differentiation and others, were analyzed (Table I) . A cutoff value of 0.16 was set for ΔMI and the patients were classified according to the mean MI of RECK in ESCC and non-tumor tissues. There was a significant difference in the AJCC stage (P<0.0001) and the stage of lymph node metastasis (P=0.001) between cases where ΔMI ≤0.16 and ΔMI >0. 16 . These results suggest that RECK hypermethylation may occur more frequently in ESCC patients with advanced tumors and lymph node metastasis.
Subsequently, associations between the RECK MI and postoperative outcomes were assessed using the Kaplan-Meier method and log-rank test (Fig. 2) RECK mRNA expression level in tissues. qPCR was performed to quantify the relative mRNA expression levels of RECK in 310 ESCC and matched non-tumor tissues. The RECK mRNA expression levels are shown in Fig. 3 . The mean -∆Cq RECK mRNA expression level was -4.66 (95% CI=-4.92 to -4.39) in ESCC tissues and -2.79 (95% CI=-3.08 to -2.50) in non-tumor tissues. There was a significant difference between ESCC tissues and matching non-tumor tissues (P<0.0001; Fig. 3) . Furthermore, the RECK mRNA expression level was increased (-∆∆Cq >0) in 130 patients (41.94%), but decreased (-∆∆Cq ≤0) in 150 patients (58.06%). These results suggest that RECK mRNA expression may be an important factor for ESCC.
RECK mRNA is associated with the clinical features of ESCC. The relationship between the mRNA expression level of RECK and clinical factors was evaluated for 310 tumor tissues. These analyses are summarized in Table II . There was a significant difference in the mRNA expression levels of RECK between ESCC patients with N 0-1 and N 2-3 stages of lymph node metastasis. A lower mRNA expression level of RECK (-ΔΔCq ≤0) was observed in 67/148 (43.24%) The association between RECK mRNA expression and survival in patients with ESCC was assessed using the Kaplan-Meier method and log rank test (Fig. 4) . Decreased RECK mRNA expression (-∆∆Cq <0) was significantly correlated with a poor overall survival [37 vs. 41 months; P=0.0014; HR=0.586 (95% CI=0.42 to 0.81)]. In addition, ESCC patients with -∆Cq RECK ≤-4.66 had a shorter median cumulative survival time compared with those with -∆Cq RECK >-4.66 [35 vs. 42 months; log-rank P<0.0001; HR= 0.379 (95% CI=0.26 to 0.55)]. These results suggest that RECK mRNA silencing may have an important role in the poor survival of patients with ESCC.
Decreased R E CK m R NA expression a n d R E CK hypermethylation in ESCC.
Subsequently, the association between the MI and mRNA expression of RECK was investigated (Fig. 5) . Notably, the mRNA expression levels of RECK were lower in ESCC tissues with ΔMI >0.16 [mean -∆∆Cq =-2.85; 95% CI=-3.48 to 2.21) compared with ESCC tissues with ΔMI ≤0.16 [mean -∆∆Cq = -0.83; 95% CI= -1.43 to -0.23; P<0.0001; Fig. 5A ]. There was a decreasing tendency for RECK mRNA expression from promoter hypermethylation to hypomethylation in ESCC tissues. A decreased RECK mRNA expression level was significantly associated with the demethylation status of RECK in ESCC patients (R 2 =0.086; P<0.0001; Fig. 5B ; R 2 =0.098; P<0.0001; Fig. 5C ). However, there was no significant association between the demethylation status of RECK and mRNA expression in non-tumor tissues (R 2 =0.00039; P=0.728; Fig. 5D ). These results suggest that promoter hypermethylation may be an important factor for RECK silencing in ESCC.
Discussion
RECK, as a tumor-related gene, has an important role in regulating the invasion and metastasis of tumor cells. RECK is widely expressed in normal tissues, but is significantly reduced in tumor tissues (26) . In a previous study, the RECK expression level was inversely correlated with the MMP9 expression level in nasopharyngeal carcinoma (27) . Furthermore, there was a significant association between the positive expression of RECK and that of MMP2 in adenoid cystic carcinoma (28) . These findings suggest that RECK has an important role in regulating the proliferation and migration of normal epithelial cells and carcinoma cells (29) . Therefore, understanding RECK expression is useful for delineating the molecular basis of malignancies. A previous study detected RECK methylation in 27.5% of adjacent normal mucosa samples and 47.5% of gastric cancer samples (30) . Non-small cell lung cancer (NSCLC) patients with RECK methylation exhibited lower RECK mRNA expression compared with patients with promoter hypomethylation (31) . RECK methylation was detected in 63.6% (35/55) of lung cancer specimens, and the methyltransferase inhibitor 5'-azacytidine was shown to upregulate RECK expression and reduce the invasive ability of NSCLC cells (17) . In the present study, the mean MI of the RECK promoter was 0.65 in ESCC and 0.49 in non-tumor samples. Furthermore, there was a significant association between the MI of RECK and AJCC stage and lymph node metastasis in ESCC patients, with ESCC patients with RECK hypomethylation tending to show better survival.
The present study demonstrated that RECK mRNA expression was lower in ESCC tissues compared with non-tumor tissues. In addition, patients with lymph node metastasis showed a lower RECK mRNA expression level, and ESCC patients with high RECK mRNA expression showed better survival. Therefore, RECK silencing may have an important role in the pathogenesis of ESCC. In the present study, the mRNA expression level of RECK was lower in ESCC patients with hypermethylation (∆MI >0.16; mean -∆∆Cq =-2.85) compared with those with hypomethylation (∆ MI ≤0.16; mean -∆∆Cq =-0.83), and there was a decreased tendency for RECK mRNA expression in ESCC patients with promoter hypermethylation (P<0.0001). These results suggested that hypermethylation of RECK gene may lead to RECK silencing in ESCC, and RECK expression could be regulated by DNA methylation in ESCC.
In conclusion, RECK methylation was frequently observed in ESCC and was associated with the downregulation of its mRNA expression, which was significantly correlated with a poor survival in ESCC. Further studies are required to elucidate the detailed mechanism of promoter methylation and RECK mRNA expression in ESCC.
